Cargando…

Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

The new Omicron variant of SARS-CoV-2, first identified in November 2021, is rapidly spreading all around the world. Omicron has become the dominant variant of SARS-CoV-2. There are many ongoing studies evaluating the effectiveness of existing vaccines. Studies on the neutralizing activity of vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lapa, Daniele, Grousova, Daria M., Matusali, Giulia, Meschi, Silvia, Colavita, Francesca, Bettini, Aurora, Gramigna, Giulia, Francalancia, Massimo, Garbuglia, Anna Rosa, Girardi, Enrico, Puro, Vincenzo, Antinori, Andrea, Kovyrshina, Anna V., Dolzhikova, Inna V., Shcheblyakov, Dmitry V., Tukhvatulin, Amir I., Zubkova, Olga V., Gushchin, Vladimir A., Logunov, Denis Y., Naroditsky, Boris S., Vaia, Francesco, Gintsburg, Alexander L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144866/ https://www.ncbi.nlm.nih.gov/pubmed/35632574 http://dx.doi.org/10.3390/vaccines10050817

Ejemplares similares

Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial – Authors' reply
por: Logunov, Denis Y, et al.
Publicado: (2021)

Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up
por: Matusali, Giulia, et al.
Publicado: (2022)

Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
por: Tukhvatulin, Amir I., et al.
Publicado: (2022)

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
por: Tukhvatulin, Amir I., et al.
Publicado: (2021)

Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein
por: Ozharovskaia, T. A., et al.
Publicado: (2019)

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants
por: Gushchin, Vladimir A., et al.
Publicado: (2021)

Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis
por: Burmistrova, Daria A., et al.
Publicado: (2016)

Toll-Like Receptors (TLRs): The Role in Tumor Progression
por: Shcheblyakov, D.V., et al.
Publicado: (2010)

Preclinical Studies of Immunogenity, Protectivity, and Safety of the Combined Vector Vaccine for Prevention of the Middle East Respiratory Syndrome
por: Dolzhikova, I. V., et al.
Publicado: (2020)

Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy
por: Gushchin, Vladimir A., et al.
Publicado: (2022)

Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay
por: D’Apice, Luciana, et al.
Publicado: (2022)

Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses
por: Tukhvatulin, Amir I., et al.
Publicado: (2016)

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
por: Favorskaya, Irina A., et al.
Publicado: (2022)

Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study
por: Tukhvatulin, Amir I., et al.
Publicado: (2023)

Sputnik Light and Sputnik V Vaccination Is Effective at Protecting Medical Personnel from COVID-19 during the Period of Delta Variant Dominance
por: Sukhikh, Gennady T., et al.
Publicado: (2022)

rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
por: Esmagambetov, Ilias B., et al.
Publicado: (2023)

Virus-Vectored Ebola Vaccines
por: Dolzhikova, I.V., et al.
Publicado: (2017)

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
por: Fomina, Daria S., et al.
Publicado: (2023)

Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level
por: Godkov, Mikhail A., et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization after Third Dose Vaccination in PLWH
por: Vergori, Alessandra, et al.
Publicado: (2022)

Adjuvantation of an Influenza Hemagglutinin Antigen with TLR4 and NOD2 Agonists Encapsulated in Poly(D,L-Lactide-Co-Glycolide) Nanoparticles Enhances Immunogenicity and Protection against Lethal Influenza Virus Infection in Mice
por: Tukhvatulin, Amir, et al.
Publicado: (2020)

NOD1/2 and the C-Type Lectin Receptors Dectin-1 and Mincle Synergistically Enhance Proinflammatory Reactions Both In Vitro and In Vivo
por: Tukhvatulin, Amir I, et al.
Publicado: (2020)

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
por: Logunov, Denis Y, et al.
Publicado: (2020)

Stimulation of Dectin-1 and Dectin-2 during Parenteral Immunization, but Not Mincle, Induces Secretory IgA in Intestinal Mucosa
por: Dzharullaeva, Alina S., et al.
Publicado: (2018)

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
por: Logunov, Denis Y, et al.
Publicado: (2021)

Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance
por: Shkoda, Andrey S., et al.
Publicado: (2022)

Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors’ reply
por: Logunov, Denis Y, et al.
Publicado: (2020)

Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice
por: Godakova, Svetlana A., et al.
Publicado: (2019)

The arrival of Sputnik V
por: Balakrishnan, Vijay Shankar
Publicado: (2020)

Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection
por: Voronina, Daria V., et al.
Publicado: (2022)

Torquetenovirus Loads in Peripheral Blood Predict Both the Humoral and Cell-Mediated Responses to SARS-CoV-2 Elicited by the mRNA Vaccine in Liver Transplant Recipients
por: Minosse, Claudia, et al.
Publicado: (2023)

Rapid and qualitative identification of SARS-CoV-2 mutations associated with variants of concern using a multiplex RT-PCR assay coupled with melting analysis
por: Sberna, Giuseppe, et al.
Publicado: (2022)

Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection
por: Esmagambetov, I. B., et al.
Publicado: (2021)

Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding
por: Lapa, Daniele, et al.
Publicado: (2022)

Phenotypic Changes in T and NK Cells Induced by Sputnik V Vaccination
por: Boyko, Anna A., et al.
Publicado: (2023)

SARS-CoV-2 Variants Identification: Overview of Molecular Existing Methods
por: Berno, Giulia, et al.
Publicado: (2022)

Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection
por: Koroleva, Ekaterina A., et al.
Publicado: (2017)

Triggering of Toll-like Receptor-2 in Mouse Myelomonocytic Leukaemia Cells WEHI-3B Leads to the Suppression of Apoptosis and Promotes Tumor Progression in Vivo
por: Shcheblyakov, D.V., et al.
Publicado: (2011)

Sputnik V vaccine goes global
por: Lawton, Graham
Publicado: (2021)

Controversy surrounding the Sputnik V vaccine
por: Cazzola, Mario, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e2p8ij3ltevgrikrk38pnceg22